Our team is ready to assist you with your health and wellness goals
In Phase 2 trials, participants lost up to 24% of their total body weight over 48 weeks at higher doses more than with any other GLP-based medication so far
HM15275 and HM17321, both scheduled for presentation at ADA 2025, represent next-generation pipelines following the innovation of efpeglenatide, which is targeted for commercialization in the second half of 2026
Whether you're balancing family commitments in the Museum District or managing a busy professional life downtown, our streamlined approach fits your lifestyle
Li S, Wang M, Ma J, Pang X, Yuan J, Pan Y, et al
GLP-1, yemek yedikten sonra barsaklardan salglanr ve vcuda besin alnd sinyali gnderir